Rizzetto Mario
Recenti Prog Med. 2014 Jun;105(6):225-6. doi: 10.1701/1543.16847.
New hepatitis C therapies have recently become available that allow to treat almost all infected patients. The excellent results can be obtained with negligible side effects and no danger of drug interactions. As a consequence, combinations of new direct acting antivirals against hepatitis C virus (HCV) can provide an effective treatment of chronic viral infections. However, such therapeutic potentialities should be weighed against economic constraints that prevent widespread use of these agents. The new drugs may not be used for the treatment of tens of thousands of HCV cases in Italy, and it is likely that reimbursement will be only for patients with advanced liver disease due to HCV. Contemporary medicine has reached a milestone unthinkable only a few years ago, but the paradox of our times is that only a few patients can benefit of it.
最近出现了新的丙型肝炎治疗方法，几乎可以治疗所有受感染患者。这些方法能取得极佳效果，副作用可忽略不计，且不存在药物相互作用的风险。因此，新型直接作用抗丙型肝炎病毒（HCV）药物的联合使用可为慢性病毒感染提供有效治疗。然而，这种治疗潜力应与阻碍这些药物广泛使用的经济限制因素相权衡。在意大利，这些新药可能不会用于治疗数以万计的丙型肝炎病例，而且很可能仅为因丙型肝炎导致晚期肝病的患者提供报销。当代医学已达到仅在几年前还无法想象的一个里程碑，但我们这个时代的悖论在于只有少数患者能从中受益。
